middle.news
How Anatara Lifesciences’ Hong Kong Patent Boosts GaRP’s Global Potential
2:13am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How Anatara Lifesciences’ Hong Kong Patent Boosts GaRP’s Global Potential
2:13am on Monday 2nd of June, 2025 AEST
Key Points
Hong Kong patent granted for GaRP, valid until 2040
Previous patents secured in Europe and Australia
GaRP targets gastrointestinal disorders including IBS
Market opportunity for non-prescription GI products valued at US$8 billion in the US
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE